182 related articles for article (PubMed ID: 11525944)
1. Fragile histidine triad gene and skin cancer.
Zanesi N; Croce CM
Eur J Dermatol; 2001; 11(5):401-4. PubMed ID: 11525944
[TBL] [Abstract][Full Text] [Related]
2. The Fragile Histidine Triad gene and breast cancer.
Yang Q; Yoshimura G; Sakurai T; Kakudo K
Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
[TBL] [Abstract][Full Text] [Related]
3. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells.
Ishii H; Dumon KR; Vecchione A; Trapasso F; Mimori K; Alder H; Mori M; Sozzi G; Baffa R; Huebner K; Croce CM
Cancer Res; 2001 Feb; 61(4):1578-84. PubMed ID: 11245468
[TBL] [Abstract][Full Text] [Related]
4. A mouse model of the fragile gene FHIT: From carcinogenesis to gene therapy and cancer prevention.
Zanesi N; Pekarsky Y; Croce CM
Mutat Res; 2005 Dec; 591(1-2):103-9. PubMed ID: 16085127
[TBL] [Abstract][Full Text] [Related]
5. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer.
Dumon KR; Ishii H; Vecchione A; Trapasso F; Baldassarre G; Chakrani F; Druck T; Rosato EF; Williams NN; Baffa R; During MJ; Huebner K; Croce CM
Cancer Res; 2001 Jun; 61(12):4827-36. PubMed ID: 11406559
[TBL] [Abstract][Full Text] [Related]
6. [FHIT--tumor suppressor protein involved in induction of apoptosis and cell cycle regulation].
Pecherzewska R; Nawrot B
Postepy Biochem; 2009; 55(1):66-75. PubMed ID: 19514467
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of the fragile histidine triad (FHIT) tumor suppressor gene in vesical tumors of cattle with chronic enzootic hematuria (CEH).
Guidi E; Uboldi C; Ferretti L
Cytogenet Genome Res; 2008; 120(1-2):173-7. PubMed ID: 18467844
[TBL] [Abstract][Full Text] [Related]
8. FHITness and cancer.
Druck T; Berk L; Huebner K
Oncol Res; 1998; 10(7):341-5. PubMed ID: 10063967
[TBL] [Abstract][Full Text] [Related]
9. The murine Fhit gene is highly similar to its human orthologue and maps to a common fragile site region.
Glover TW; Hoge AW; Miller DE; Ascara-Wilke JE; Adam AN; Dagenais SL; Wilke CM; Dierick HA; Beer DG
Cancer Res; 1998 Aug; 58(15):3409-14. PubMed ID: 9699673
[TBL] [Abstract][Full Text] [Related]
10. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers.
Turner BC; Ottey M; Zimonjic DB; Potoczek M; Hauck WW; Pequignot E; Keck-Waggoner CL; Sevignani C; Aldaz CM; McCue PA; Palazzo J; Huebner K; Popescu NC
Cancer Res; 2002 Jul; 62(14):4054-60. PubMed ID: 12124341
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of the human fragile histidine triad gene at 3p14.2 in monochromosomal human/mouse microcell hybrid-derived severe combined immunodeficient mouse tumors.
Kholodnyuk ID; Szeles A; Yang Y; Klein G; Imreh S
Cancer Res; 2000 Dec; 60(24):7119-25. PubMed ID: 11156420
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines.
Tamura G; Sakata K; Nishizuka S; Maesawa C; Suzuki Y; Iwaya T; Terashima M; Saito K; Satodate R
Genes Chromosomes Cancer; 1997 Sep; 20(1):98-102. PubMed ID: 9290961
[TBL] [Abstract][Full Text] [Related]
13. Implication of mitochondrial involvement in apoptotic activity of fragile histidine triad gene: application of synchronous luminescence spectroscopy.
Askari MD; Vo-Dinh T
Biopolymers; 2004 Mar; 73(4):510-23. PubMed ID: 14991669
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
[TBL] [Abstract][Full Text] [Related]
15. Comparative genomic mapping of the bovine Fragile Histidine Triad (FHIT) tumour suppressor gene: characterization of a 2 Mb BAC contig covering the locus, complete annotation of the gene, analysis of cDNA and of physiological expression profiles.
Uboldi C; Guidi E; Roperto S; Russo V; Roperto F; Di Meo GP; Iannuzzi L; Floriot S; Boussaha M; Eggen A; Ferretti L
BMC Genomics; 2006 May; 7():123. PubMed ID: 16719907
[TBL] [Abstract][Full Text] [Related]
16. FHIT gene in gastric cancer: association with tumour progression and prognosis.
Noguchi T; Müller W; Wirtz HC; Willers R; Gabbert HE
J Pathol; 1999 Aug; 188(4):378-81. PubMed ID: 10440747
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of fragile histidine triad expression in prostate carcinoma.
Fouts RL; Sandusky GE; Zhang S; Eckert GJ; Koch MO; Ulbright TM; Eble JN; Cheng L
Cancer; 2003 Mar; 97(6):1447-52. PubMed ID: 12627509
[TBL] [Abstract][Full Text] [Related]
18. Identification of unstable sequences within the common fragile site at 3p14.2: implications for the mechanism of deletions within fragile histidine triad gene/common fragile site at 3p14.2 in tumors.
Corbin S; Neilly ME; Espinosa R; Davis EM; McKeithan TW; Le Beau MM
Cancer Res; 2002 Jun; 62(12):3477-84. PubMed ID: 12067991
[TBL] [Abstract][Full Text] [Related]
19. Induction of the common fragile site FRA3B does not affect FHIT expression.
Michael D; Rajewsky MF
Oncogene; 2001 Mar; 20(14):1798-801. PubMed ID: 11313927
[TBL] [Abstract][Full Text] [Related]
20. Alterations of the FHIT gene in human hepatocellular carcinoma.
Yuan BZ; Keck-Waggoner C; Zimonjic DB; Thorgeirsson SS; Popescu NC
Cancer Res; 2000 Feb; 60(4):1049-53. PubMed ID: 10706123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
